Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer
Clinical Lung Cancer · 2023
DOI: 10.1016/j.cllc.2023.08.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2023. Verfasst von Milena Petranovic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: mpetranovic@mgh.harvard.…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Lung Diseases, Interstitial. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION/BACKGROUND: Immune-related pneumonitis is a potentially fatal complication of treatment with immune checkpoint inhibitors (ICIs). Interstitial lung disease (ILD) is associated with increased risk for pneumonitis, but the impact of interstitial abnormalities (ILA) in the absence of ILD has not been extensively assessed. We examined the relationship between ILA on pretreatment chest computed tomography (CT) scans and risk of pneumonitis in patients with non-small-cell lung cancer (NSCLC). METHODS: This retrospective cohort study included consecutive adult patients who received ICI for NSCLC between January 2013 and January 2020 at our institution. Two thoracic radiologists blinded to clinical outcomes independently reviewed pre-ICI chest CTs to identify and categorize ILA using previously published definitions. We used uni- and multivariable analysis adjusted for age, radiation, and smoking status to assess for associations between ILA, clinicopathologic characteristics, and symptomatic (CTCAE grade ≥2) pneumonitis. RESULTS: Of 475 patients who received ICI treatment and met inclusion criteria, baseline ILA were present in 78 (16.4%) patients, most commonly as a subpleural nonfibrotic pattern. In total, 43 (9.1%) of 475 patients developed symptomatic pneumonitis. Pneumonitis occurred in 16.7% of patients with ILA compared to 7.6% patients without ILA (P < .05). Presence of ground glass and extent of lung parenchymal involvement were associated with an increased risk of pneumonitis. On multivariable analysis, baseline ILA remained associated with increased risk of symptomatic pneumonitis (OR 2.2, 95% CI, 1.0-4.5). CONCLUSIONS: Baseline ILAs are associated with the development of symptomatic pneumonitis in patients with NSCLC treated with ICI. Additional studies are needed to validate these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: mpetranovic@mgh.harvard.edu.
- Department of Radiology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA.
- Department of Radiology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Data Science Office, Mass General Brigham, Boston, MA.
- Mayo Clinic, Jacksonville, FL.
- Department of Radiology, Massachusetts General Hospital, Boston, MA.
- Harvard Medical School, Boston, MA.
Zitieren
APA
Petranovic, M., McDermott, S., Mercaldo, S., Little, B. P., Graur, A., Huang, K., Fintelmann, F. J., Digumarthy, S. R., & Gainor, J. F. (2023). Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.08.014
Vancouver
Petranovic M, McDermott S, Mercaldo S, Little BP, Graur A, Huang K, et al. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2023. doi:10.1016/j.cllc.2023.08.014
BibTeX
@article{Petranovic2023,
author = {Petranovic, Milena and McDermott, Shaunagh and Mercaldo, Sarah and Little, Brent P and Graur, Alexander and Huang, Kevin and Fintelmann, Florian J and Digumarthy, Subba R and Gainor, Justin F},
title = {Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2023},
doi = {10.1016/j.cllc.2023.08.014}
}
EUVIMED